文献速递临床微生物质量管理与危急值

培养基品牌对头孢地尔纸片扩散法结果的影响

Impact of media brand on cefiderocol disk diffusion results.
PubMed 文献 · J Clin Microbiol · 2025-03-25

本研究比较了三种商业Mueller-Hinton琼脂(Remel、Hardy、BBL)的头孢地尔纸片扩散法(DD)结果与铁耗竭肉汤微量稀释法(BMD)的一致性。仅BBL琼脂在CLSI折点下分类一致性≥90%。铜绿假单胞菌和碳青霉烯耐药肠杆菌目(CRE)的DD品牌内和品牌间变异最大。BMD非敏感菌株常与AST判读误差和较低分类一致性相关。

要点

  • 商业MHA品牌显著影响头孢地尔DD结果的重复性和判读准确性。
  • 仅BBL琼脂在CLSI折点下分类一致性≥90%,其他品牌未达标。
  • BMD非敏感菌株的DD判读错误风险更高,需谨慎解读。

核心结论

  • 使用商业MHA进行头孢地尔DD可导致频繁的AST判读差异,尤其对BMD非敏感菌株。
  • 需重新审视方法和质控以确保头孢地尔DD的可靠性。

研究设计与样本

  • 比较Remel、Hardy和BBL品牌MHA的DD结果与铁耗竭阳离子调节MHB的BMD结果。
  • 评估BMD重复性、BMD拖尾终点以及DD品牌内和品牌间抑菌圈变异。

主要发现

  • 仅BBL琼脂在CLSI折点下分类一致性≥90%。
  • DD品牌内和品牌间变异在铜绿假单胞菌和CRE中最高,分别有25%(5/20)和16.7%(3/18)出现AST判读差异。
  • BMD非敏感菌株常与AST判读误差和较低分类一致性相关。

关键数值与推荐

  • 分类一致性(CA)≥90%仅在使用BBL琼脂和CLSI折点时达到。
  • 铜绿假单胞菌中25%(5/20)和CRE中16.7%(3/18)的DD结果出现判读差异。

临床怎么用

  • 临床实验室使用商业MHA进行头孢地尔DD时需注意品牌差异对判读的影响。
  • 对BMD非敏感菌株的DD结果应谨慎解读,必要时用BMD确认。
  • 需重新评估方法和质控以确保DD可靠性。

局限性

  • 未报告其他品牌琼脂的具体分类一致性数值。
  • 未提供BMD重复性和拖尾终点的具体数据。
  • 未说明样本量是否足以推广至所有菌种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Cefiderocol is a siderophore cephalosporin that utilizes iron transport systems to cross cell membranes. This unique strategy complicates antimicrobial susceptibility testing (AST) due to variable iron content in media. While guidance for using iron-depleted media exists for broth microdilution (BMD), disk diffusion (DD) with commercial media is a common AST method in the clinical laboratory. We investigated cefiderocol DD result variability using multiple Mueller-Hinton agar (MHA) brands. DD results using Remel (Thermo Fisher Scientific, San Diego, CA), Hardy (Hardy Diagnostics, Springboro, OH), and BBL (Becton Dickinson, East Rutherford, NJ) MHA were compared to those of BMD using iron-depleted cation-adjusted Mueller-Hinton broth. BMD reproducibility, BMD trailing endpoints, and DD intra- and inter-brand variability in zones of inhibition were investigated. Forty-seven multidrug-resistant clinical isolates and three Antibiotic Resistance Bank isolates composed of Pseudomonas aeruginosa, carbapenemase (CP-) and non-carbapenemase-producing (non-CP-) carbapenem-resistant Enterobacterales (CRE), Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex were tested. Categorical agreement (CA) ≥ 90% was only demonstrated using CLSI breakpoints with BBL agar. Intra- and inter-brand variability in DD were highest for P. aeruginosa and CRE, with 25% (5/20) and 16.7% (3/18) exhibiting discrepant AST interpretations, respectively. Isolates not susceptible to cefiderocol via BMD were commonly associated with AST interpretation errors and lower CA. Using commercial MHA for DD resulted in frequent AST interpretation discrepancies, particularly for isolates that were not susceptible to cefiderocol by BMD. Methods and quality control may need to be revisited to ensure the reliability of DD for cefiderocol AST. IMPORTANCE: The novel mechanism of action of cefiderocol overcomes a variety of resistance mechanisms associated with gram-negative bacteria and positions the agent as an attractive option for treating infections involving multidrug-resistant pathogens. The availability of accurate, timely antimicrobial susceptibility testing methods for cefiderocol in clinical microbiology laboratories is critical as cefiderocol-resistant isolates have been described and may contribute to treatment failure. Iron-depleted broth microdilution testing may not be feasible for use in many clinical laboratories. While disk diffusion is an appealing, practical method to implement, our data demonstrate reproducibility issues across agar brands, most notably for organisms that do not test susceptible to cefiderocol when using broth microdilution. Discrepancy errors and misclassifications of resistant isolates as susceptible, and susceptible isolates as resistant, may mislead clinicians and compromise the treatment efficacy. More work is needed to standardize practical yet reproducible methods for cefiderocol antimicrobial susceptibility testing.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. DeMarco MG, Field AM, Donohue LE, et al. Impact of media brand on cefiderocol disk diffusion results. J Clin Microbiol. 2025. PMID: 40130882. doi:10.1128/jcm.01648-24

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。